To report 5 cases of inflammatory early postoperative IOL opacification in a series of 897 consecutive phaco surgeries
Methods
Single center, consecutive, case series. Internal and external audit of the procedures
Results
All 897 cases were operated on using the same viscoelastic, IOL model and intraocular solution. IOL opacification occurred to 4 different surgeons in Sep 2018, Dec 2018, Mar 2019, May 2019 and Jul 2019, after uneventful surgery and were identified at the scheduled visit between 1 and 2 months after surgery. Patients presented with a thin fibrinous membrane on the anterior surface of the IOL and mild flare. They were treated with topical steroids (5 cases), Nd-YAG laser anterior to the IOL surface (3 cases), transTenon triamcinolone (1 case) and anterior chamber rinse (1 case) that was negative for bacterial or fungal culture. Final corrected visual acuity was between 4/8 and 4/5. None of the patients experienced recurrences or similar events during fellow eye surgery.
None of the patients had history of systemic or ocular inflammatory conditions or previous intraocular procedures. In 3 patients It was associated with pseudoexfoliation and in 2 cases with atrophic AMD.
A thorough audit of the surgical and sterilization procedures and adjuvant materials used during the surgeries was performed by two teams (internal and external) and no causes were found that might be related to the occurrence of these inflammatory events.
No similar cases have been identified since, even though the same procedures have been maintained
Conclusion
We report 5 cases of early postoperative inflammation with IOL opacification successfully treated by topical steroids combined with other minor procedures. The cause of IOL opacification has remained unknown.
Conflict of interest
No
Authors 1
Last name
MONTERO-MORENO
Initials of first name(s)
J
Department
Ophthalmology. Rio Hortega Hospital
City
Valladolid
Country
Spain
Authors 2
Last name
Diez-Montero
Initials of first name(s)
C
Department
Ophthalmology. Rio Hortega Hospital
City
Valladolid
Country
Spain
Authors 3
Last name
Sanchis-Merino
Initials of first name(s)
ME
Department
Allergy and Clinical Immunology. Rio Hortega Hospital
City
Valladolid
Country
Spain
Authors 4
Last name
Gonzalez-Uruena
Initials of first name(s)
C
Department
Ophthalmology Clinical Trials Unit. Rio Hortega Hospital
City
Valladolid
Country
Spain
Authors 5
Last name
Hernandez-Fernandez
Initials of first name(s)
R
Department
Ophthalmology Clinical Trials Unit. Rio Hortega Hospital
City
Valladolid
Country
Spain
Authors 6
Last name
Cañibano-Perez
Initials of first name(s)
E
Department
Ophthalmology Clinical Trials Unit. Rio Hortega Hospital
City
Valladolid
Country
Spain
This website uses cookies to ensure you get the best experience on our website.
Learn more